Trial Profile
Efficacy and safety of ODM-101 compared to a standard combination (Stalevo); a randomised, double-blind, crossover, proof of concept study in patients with Parkinson's disease and end-of-dose motor fluctuations.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Mar 2019
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa/entacapone (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms PARPOC
- Sponsors Orion Pharma
- 01 Mar 2019 Results published in the Neurology
- 23 Mar 2013 Primary endpoint 'Off-time' has been met.
- 23 Mar 2013 Results presented at the 65th Annual Meeting of the American Academy of Neurology.